Background Inherited thrombophilias are well‐established predisposing factors for venous
thromboembolism, but their role in arterial thrombosis, such as arterial ischemic stroke …

This new edition of the World Federation of Hemophilia (WFH) guidelines for the
management of hemophilia comes at an exciting time in the evolution of the diagnosis and …

Against a background of a rapidly evolving treatment landscape, a contemporary, evidence‐
based consolidated understanding of mortality in people with congenital hemophilia A …

Factor VIII protein (FVIII) as a coagulation replacement factor has for decades been used as
the standard of care for management of people with haemophilia A. It is effective for …

Cardiovascular disease is an emerging medical issue in patients with hemophilia (PWH)
and its prevalence is increasing up to 15% in PWH in the United States. Atrial fibrillation …

Introduction We conducted six cross‐sectional nationwide questionnaire studies among all
patients with hemophilia in the Netherlands from 1972 until 2019 to assess how health …

Abstract Introduction Emicizumab (Hemlibra™) is approved for prophylaxis of Haemophilia
A (HA) patients with and without inhibitors. However, real‐world data on emicizumab use in …

Hemophilia is a congenital bleeding disorder caused by low levels of clotting factor VIII or IX.
The life expectancy of people with hemophilia (PWH) has increased with the availability of …

With the introduction of clotting factor concentrates in the early 1970s, significant
improvements in quality of life and life expectancy of persons with haemophilia (PWH) were …

In persons with congenital severe hemophilia A (HA) living in high-income countries, twice
weekly intravenous infusions of extended half-life (EHL) factor VIII (FVIII) products, or …